About Us:
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company leveraging a transformational drug development strategy focused on the prevention or interception of immune-mediated disease.
Provention's diversified portfolio includes teplizumab, a pre-commercial-stage candidate that has been shown to delay the onset of insulin-dependent type 1 diabetes (T1D) in at-risk patients during the presymptomatic phase of the disease.
The Company's portfolio also includes additional clinical product development candidates that have demonstrated proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.
For more information, visit www.Proventionbio.com.
Address:
55 Broad Street, 2nd Floor, Red Bank, NJ 07701
Phone:
908.336.0360
Email:
Website:
Brief summary of the video content:
Type 1 Diabetes (T1D) Pathogenesis and Screening
Pathogenesis of T1D and Risk of Progression
Review spectrum of T1D by pathogenesis with each of the stages, including Stage 1 (antibody positive with normoglycemia), Stage 2 (beta cell destruction leading to dysglycemia) and Stage 3 of T1D (beta cell destruction leading to clinical diabetes). Will discuss the risk of clinical T1D with the presence of antibodies.
Lessons Learned from Large Screening Studies
Will summarize relevant data from large screening studies for T1D and the benefits of screening including the opportunity to monitor patients for the development of symptoms, provide education, recognize symptoms before the development of DKA and improved long term glycemic control.
Who Should be Screened?
Will discuss the cost effectiveness and efficiency of screening relatives of patients with T1D.
Availability of Screening
Discussion of current availability of T1D autoantibody tests and the range of options that include laboratory blood draws and at-home testing kits. Access to testing by those at risk may be limited and may improve if screening is recommended by national guidelines.
Therapies in Development for Early Stages of T1D
Discussion of the landscape of clinical trials for disease-modifying treatment options underway. Anticipate treatments to supplement, reduce, or possibly delay the need for insulin administration likely on the market within the next 6-12 months.
Media:
Have questions? please contact:
For General Inquiries:
info@proventionbio.com
For Investor Relations/Media Communications:
RDoody@proventionbio.com
For Human Resources:
HumanResources@proventionbio.com
For Business Development:
BusinessDevelopment@proventionbio.com
For Medical Affairs:
MedAffairs@proventionbio.com
Enter the MAP Spotlight Raffle